Seelos Therapeutics Reschedules Annual Meeting
Seelos Therapeutics, Inc. (OTCQB: SEEL), a clinical-stage biopharmaceutical company dedicated to the development of therapies for central nervous system disorders and rare diseases, has made an important announcement regarding its Annual Meeting of Stockholders. Initially postponed, the meeting is now set to take place virtually on Monday, November 25, 2024, at 8:00 a.m. Eastern Time.
Details of the Annual Meeting
The decision to postpone the Annual Meeting was made to address anticipated quorum issues and to allow more time for Seelos to solicit votes from its stockholders. All stockholders are encouraged to cast their votes, as the company will ensure that votes are counted during the postponed meeting. Those who previously voted are not required to re-cast their votes unless they want to update their preferences.
Importance of Participation
Seelos values the input and participation of its stakeholders and encourages all stockholders to actively engage in this pivotal meeting. By voting, stockholders significantly contribute to the direction and governance of the company, ensuring their interests are represented. The company has emphasized the importance of voting on the proposed Board of Director nominees and other key proposals detailed in the proxy statement.
About Seelos Therapeutics
Seelos Therapeutics is at the forefront of biopharmaceutical innovation, focusing on developing new therapeutic options for patients suffering from central nervous system disorders and rare diseases. The company is committed to meeting the unmet medical needs of patients and driving forward its promising pipeline.
Resources for Stockholders
Stockholders can find additional information and updates on the Seelos Therapeutics website. It is essential for stockholders to stay informed and review the materials related to the forthcoming Annual Meeting. This includes the definitive proxy statement, which provides details on the proposals that will be put forth at the meeting.
Contact Information
If stockholders or interested parties have inquiries, they can reach out to Mike Moyer, Managing Director at LifeSci Advisors, LLC. Seelos is dedicated to maintaining transparency and communication with its stakeholders, fostering an open dialogue as it navigates the complexities of the biopharmaceutical landscape.
Frequently Asked Questions
What is the date of the rescheduled Seelos Annual Meeting?
The rescheduled Annual Meeting of Stockholders will take place on November 25, 2024.
Why was the Annual Meeting postponed?
The meeting was postponed to ensure there would be a quorum and to allow for additional proxy solicitations from stockholders.
How can stockholders vote?
Stockholders can vote by following the instructions provided in the proxy materials sent to them. Those who have already voted do not need to take any action unless they wish to change their vote.
What is the role of the Board of Directors in the meeting?
The Board of Directors is recommending that stockholders vote in favor of the nominees and proposals outlined in the proxy statement as part of the meeting.
Where can stockholders find additional resources?
Stockholders can visit the Seelos Therapeutics website for more information and updates regarding the Annual Meeting and relevant proxy materials.
